Analystreport

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock.

Jazz Pharmaceuticals plc - Ordinary Shares  (JAZZ) 
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: jazzpharma.com